NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-08-31
Reading DXR? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →Intact: The reason to own it still holds.
Daxor is improving revenue from $11.9M in 2026 to $20.8M in 2027. Losses are shrinking with EPS improving from -$0.21 to -$0.03. The company has stable management and no recent negative news. Its valuation is slightly below peers, offering upside if turnaround succeeds.
Daxor remains unprofitable with negative free cash flow and high risk. Revenue growth is uncertain with only one analyst covering. The stock is volatile and the turnaround may stall or fail.
The price is about 6% above our fair value near $9.8, reflecting modest optimism. The market expects very low growth and continued losses, which matches the cautious outlook.
Breaks if: EPS remains below -$0.10 in FY27
Breaks if: FCF yield remains below -2% over next 4 quarters
Breaks if: revenue falls below $15M in FY27
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
DXR is positioned as a smaller-cap name in the healthcare sector, which is currently benefiting from a favorable backdrop. However, the investment thesis is in a state of uncertainty due to recent earnings volatility and mixed signals from larger sector players.
The current valuation reflects a premium compared to peers, indicating that the market has some positive expectations priced in. However, there is low fragility in the current market regime, suggesting that the stock is not overly sensitive to adverse developments.
Management appears stable, but the high risk associated with the stock could lead to erratic performance in the near term. The recent rise in valuation suggests that the market is cautiously optimistic, but the lack of recent financial performance history makes it difficult to gauge future fundamentals.
The future performance of DXR will depend significantly on the earnings results and guidance from larger healthcare companies like ISRG, BDX, and RMD. Additionally, any signs of a weakening job market could negatively impact sentiment and performance in the sector.
In the next 1 to 3 years, DXR's outlook will largely depend on external sector dynamics and broader economic conditions. Not investment advice.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-08-31
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
